URGN — UroGen Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1668243 ·
Last close
$29.87
Market Cap
$1.47B
52W High
$50.81
52W Low
$16.50
ADV30
1,415,687
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 89,001,000 | 81,499,000 | 8,329,000 | -1,462,000 | 271,873,000 | 85,564,000 | 397,090,000 |
| Jun 2026 | 72,456,000 | 65,884,000 | 111,000 | -14,351,000 | 252,590,000 | 79,133,000 | 384,986,000 |
| Mar 2026 | 50,959,000 | 46,820,000 | -20,263,000 | -23,574,000 | 253,690,000 | 109,968,000 | 377,943,000 |
| Dec 2025 | 37,837,000 | 34,548,000 | -19,115,000 | -26,364,000 | 200,455,000 | 110,745,000 | 305,929,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,846,000
Investing CF
$28,556,000
Financing CF
$98,798,000
CapEx
$-203,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.32
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-999,103,000
Inventory
$25,150,000
Receivables
$117,283,000
ST Investments
$4,985,000
EBIT TTM
$-46,473,000
Pretax Income TTM
$-64,153,000
Interest Exp TTM
$17,680,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$250,252,992
EBITDA
$-30,629,000
Free Cash Flow
$-97,182,248
Enterprise Value
$1,319,667,584
Total Cash
$90,549,000
Total Debt
$196,283,008
Shares Out
49,047,823
Trailing EPS
$-1.31
Book Value
$-2.55
ROE
—
ROA
-8.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,788,000 | -124,863,000 | -153,494,000 | 200,455,000 | 305,929,000 | -105,474,000 | -162,444,000 |
| Dec 2024 | 90,398,000 | -96,782,000 | -126,874,000 | 285,711,000 | 294,514,000 | -8,803,000 | -96,766,000 |
| Dec 2023 | 82,713,000 | -65,536,000 | -102,244,000 | 178,311,000 | 243,523,000 | -65,212,000 | -76,376,000 |
| Dec 2022 | 64,357,000 | -79,041,000 | -109,783,000 | 135,619,000 | 224,980,000 | -89,361,000 | -87,559,000 |
TTM Snapshot
Revenues TTM
$188,734,000
NetIncome TTM
$-97,636,000
OpCashFlow TTM
—
Assets (Latest)
$252,590,000
Forward EPS
$2.80
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $29.79 · call volume: 275 · put volume: 322
Expected Move to 2027-01-15:
±$4.90
(16.45%) —
implied range
$24.89 –
$34.69
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QURE | uniQure N.V. | $1.46B | $20.78 | — |
| PCRX | Pacira BioSciences, Inc. | $1.46B | $36.48 | — |
| KRSA | Korsana Biosciences, Inc. | $1.48B | $32.50 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.41B | $23.76 | — |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.53B | $13.82 | — |
News headlines (Yahoo Finance, 1h cache)
UroGen Pharma (URGN) Stock Could Be A Bargain Following Its 148% Run
2026-11-18 00:24 · Yahoo
UroGen Pharma Ltd (URGN) (Q3 2026) Earnings Call Highlights: Zysturi's 35% Sequential Surge and ...
2026-11-05 03:09 · Yahoo
Earnings Beat Might Change The Case For Investing In UroGen Pharma (URGN)
2026-11-05 01:13 · Yahoo
Urogen Pharma Q3 Earnings Call Highlights
2026-11-04 22:14 · Yahoo
The Gel That Became a Business
2026-11-04 21:50 · Yahoo
UroGen (URGN) Q3 2026 Earnings Call Transcript
2026-11-04 20:14 · Yahoo
Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 14:05 · Yahoo
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
2026-11-04 13:00 · Yahoo
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
2026-11-03 13:00 · Yahoo
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
2026-10-28 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.